Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab for Asymptomatic Radiotherapy-induced Brain Injury
NCT05303259Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Nov 2021
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in Radiation-Induced Brain Injury (RIBI), sponsored by Sun Yat-sen Memorial Hospital. Started Nov 2021; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
Radiation-Induced Brain Injury (RIBI)
Beyond the preview
Go deeper on NCT05303259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05303259.